REVIEW article
Front. Aging Neurosci.
Sec. Alzheimer's Disease and Related Dementias
Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1609063
This article is part of the Research TopicAI-Enhanced Biomarkers: Revolutionizing Early Detection and Precision Medicine in NeurodegenerationView all articles
Artificial Intelligence Technologies for Enhancing Neurofunctionalities: A Comprehensive Review with Applications in Alzheimer’s Disease Research
Provisionally accepted
- Gansu Provincial Hospital, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Alzheimer’s Disease (AD) is a progressive neurodegenerative condition that impairs memory and cognition, presenting a growing global healthcare burden. Despite major research efforts, no cure exists, and treatments remain focused on symptom relief. This narrative review highlights recent advancements in artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), which enhance early diagnosis, predict disease progression, and support personalized treatment strategies. AI applications are reshaping healthcare by enabling early detection, predicting disease progression, and developing personalized treatment plans. In particular, AI's ability to analyze complex datasets, including genetic and imaging data, has shown promise in identifying early biomarkers of AD. Additionally, AI-driven cognitive training and rehabilitation programs are emerging as effective tools to improve cognitive function and slow down the progression of cognitive impairment. The paper also discusses the potential of AI in drug discovery and clinical trial optimization, offering new avenues for the development of AD treatments. However, ethical considerations such as data privacy, algorithmic bias, and challenges in integrating AI into existing healthcare frameworks remain significant. The paper emphasizes the need for ongoing interdisciplinary collaboration and regulatory oversight to harness AI's full potential in transforming AD care and improving patient outcomes.
Keywords: Alzheimer's disease, artificial intelligence, machine learning, cognitive training, used, including: "Alzheimer's Disease", "mild cognitive impairment", "dementia"
Received: 09 Apr 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Gu, Wang, Wang, Gong and Qi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhirong Gu, Gansu Provincial Hospital, Lanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.